CoChat
Sign Up
Cited by 153Schizophrenia research and treatmentPharmaceutical studies and practicesChild and Adolescent Psychosocial and Emotional Development

Second-Generation Antipsychotic Medications in Children and Adolescents

Cheng-Shannon, Jennifer, McGough, James J., Pataki, Caroly, McCracken, James T.·2004·Journal of Child and Adolescent Psychopharmacology
DOI 10.1089/cap.2004.14.372
Open this paper in CoChat — free account

Abstract

OBJECTIVE: We reviewed available pediatric literature on second-generation antipsychotic medications to assess current evidence of efficacy and safety. METHOD: An English language MEDLINE search (1974-2003) was conducted using key words-atypical antipsychotics, children and adolescents, toxicity, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Additional efficacy and safety data were obtained from drug manufacturers. RESULTS: We identified 176 reports, including 15 double-blind, controlled trials, 58 openlabel studies, 18 retrospective chart reviews, and 85 case series/reports. The majority of these studies (43%) were of risperidone. Evidence suggests that second-generation antipsychotics are efficacious in the treatment of psychosis, bipolar disorders, pervasive developmental disorders, and Tourette's Disorder, and are potentially useful in mental retardation, conduct disorder, and severe attention deficit hyperactivity disorder (ADHD). The most frequently reported side effects included cardiovascular effects, weight gain, sedation, sialorrhea, extrapyramidal signs, and hyperprolactinemia, although the relative frequencies of these untoward effects vary among medications. CONCLUSION: Although the evidence base for pediatric use of second-generation antipsychotics is expanding, the majority of available studies are anecdotal, or short-term, openlabel trials. Reports suggest that these compounds are effective for a variety of psychiatric disorders in children and adolescents, but additional double-blind, controlled studies are required to establish definitive efficacy. Although these medications appear to be well tolerated in short-term studies, long-term follow-up investigations and ongoing clinical monitoring are necessary to confirm their safety in this age group.

Integrity signals

Registry

Crossref · 10.1089/cap.2004.14.372

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T.
Affiliations
  • University of Washington (US)
  • University of California, Los Angeles (US)
ORCID
Venue
Journal of Child and Adolescent Psychopharmacology
Publisher
SAGE Publications
Published
2004-09
Volume
14
Issue
3
Pages
372-394
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
DOI
10.1089/cap.2004.14.372
OpenAlex
W2042850223
Cited by
152
References
176
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 7 · 2013: 8 · 2012: 9
FWCI
8.92
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • Journal of Child and Adolescent Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (K23MH001966, MH10805, MH 01966)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
atypical antipsychotics, pediatric psychopharmacology, children and adolescents, risperidone, clozapine, olanzapine, quetiapine, ziprasidone, aripiprazole, efficacy, drug safety, adverse effects, psychosis, bipolar disorder, pervasive developmental disorders, Tourette syndrome, attention deficit hyperactivity disorder, conduct disorder, intellectual disability, weight gain, hyperprolactinemia, extrapyramidal symptoms
MeSH terms
Adolescent, Adult, Cardiovascular Diseases, Child, Child, Preschool, Clinical Trials as Topic, Humans, Hyperprolactinemia, Antipsychotic Agents, Weight Gain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review